The Liquid Biopsy report has been aggregated by collecting informative data of various dynamics such as market drivers, restraints, and opportunities. This innovative report makes use of several analyses to get a closer outlook on the Liquid Biopsy market. The Liquid Biopsy report offers a detailed analysis of the latest industry developments and trending factors in the market that are influencing the market growth. Furthermore, this statistical market research repository examines and estimates the Liquid Biopsy at the global and regional levels. The Global Liquid Biopsy Market was valued at approximately USD 8.1 billion in 2024 and is expected to grow at a substantial CAGR of around 13.5% during the forecast period (2025-2033)

Market Overview

The growth of the liquid biopsy market is primarily driven by increasing prevalence of cancer, growing adoption of non-invasive diagnostic and monitoring techniques and increasing preference of personalized medicines. In addition, technological advancement, increasing government initiatives to develop healthcare infrastructure and large availability funding’s for research and development for liquid biopsy is likely to contribute to the growth of liquid biopsy market during the forecast period. The growing demand for noninvasive and easy sample collection and the faster diagnosis of cancer is driving the growth of the liquid biopsy market. With huge investments and growing evidence of the uses/applications of liquid biopsy, companies are increasingly looking to move into the liquid biopsy market. the market is witnessing a surge in the number of inorganic developments such as partnerships, collaboration, agreements, mergers, and acquisitions; as many as 22 inorganic developments were recorded in this market between January and June 2017. Companies are focusing on inorganic strategies primarily to obtain access to innovative technologies of other players. Companies are also teaming up with universities and cancer institutes to gain robust R&D expertise.

Access sample report (including graphs, charts, and figures): https://univdatos.com/reports/liquid-biopsy-market?popup=report-enquiry

COVID-19 Impact

the COVID-19 pandemic has potentially affected cancer diagnosis and management. In several countries, non-essential ambulatory visits and elective surgery appointments were put on hold. Although oncological services were listed as an exception, preventive care activities such as cancer screening programs for cervical, breast, and colorectal cancer were also put on hold by decree. This had resulted in a decline in the liquid biopsy market for the initial quarters of 2020. Even so, the market is expected to gain stability and remain uninterrupted in the short term as cancer diagnostics is one of the early healthcare sectors to bounce back from the effects of the pandemic. The disease burden of cancer is growing all over the world. As per data released by the International Agency for Research on Cancer (IARC), the global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018. One in 5 men and one in 6 women worldwide develop cancer during their lifetime, and one in 8 men and one in 11 women die from the disease. The rising prevalence of cancer is the major factor driving the growth of the liquid biopsy market. Additionally, easy and non-invasive entrance to the tumor genome and novel clinical trials for research and development is likely to propel the growth of the market. For instance, In June 2020, Guardant Health presented new data demonstrating that its LUNAR-2 liquid biopsy is a highly sensitive test that can detect early-stage colorectal cancer.

Global Liquid Biopsy Market report is studied thoroughly with several aspects that would help stakeholders in making their decisions more curated.

By Cancer Type, the market is primarily bifurcated into

·        Lung

·        Breast

·        Colorectal

·        Prostate

The Lung segment dominated the type segment and gathered XX% of the Liquid Biopsy Market in 2020. Moreover, the market is expected to grow at XX% CAGR to reach US$ XX million by the year 2027.

By Circulating Biomarkers, the market is primarily segmented into

·        Circulating Tumor Cells

·        Circulating Tumor DNA

·        Cell-Free DNA

Based on the Circulating Biomarkers, the circulating tumor cells accounted for the largest share and is expected to grow at XX% CAGR during the forecast period 2021-2027. In 2020, circulating tumor DNA segment generated a revenue of US$ XX million.

By Product, the market is primarily segmented into

·        Instruments

·        Assay Kits

Based on the Product, the Instruments segment would display a significant growth rate during the forecast period with a CAGR of XX % is owing to the factors such as the increasing demand for liquid biopsy tests, increasing applications of liquid biopsies, and the need for reliable and specific assays are expected.

By End User, the market is primarily segmented into

·        Reference Laboratories

·        Hospitals and Physician Laboratories

·        Academic and Research Centers

Based on the End User, The Reference laboratories segment would display a significant growth rate during the forecast period with a CAGR of XX % is owing to the factors such as the large volume of tests being outsourced to reference laboratories from oncologists and hospitals.

Liquid Biopsy Geographical Segmentation Includes:

·        North America

·        Europe

·        Asia-Pacific

·        Rest of the World

Based on the estimation, United States dominated the North America Liquid Biopsy market and is expected to grow at a CAGR of XX% during the forecast period to reach the market value of US$ XX Bn by 2027. The growth of this region is attributed to the high incidence of cancer, easy accessibility and growing adoption of advanced diagnostic techniques. In addition, growing public and private funding to support research activities in the field of liquid biopsy contributes to the growth of this segment throughout the forecast periods. Asia-Pacific region is expected to grow at the fastest growing CAGR during the forecast period. The growth of this segment is attributed to the increasing government initiatives, growing prevalence cancer etc. Countries like China, India, and Japan are the major contributors to the growth of Asia-pacific region liquid biopsy market.

Click here to view the Report Description & TOC  https://univdatos.com/reports/liquid-biopsy-market

The major players targeting the market includes

·           Roche Diagnostics

·            Biocept, Inc.,

·            Thermo Fisher Scientific Inc.

·            Qiagen N.V.

·            Bio-Rad Laboratories, Inc.

·            Menarini-Silicon Biosystems

·            Illumina, Inc.

·            MDXhealth SA

·            Genomic Health, Inc.

·            Guardant Health Inc

Competitive Landscape

The degree of competition among prominent global companies has been elaborated by analyzing several leading key players operating worldwide. The specialist team of research analysts sheds light on various traits such as global market competition, market share, most recent industry advancements, innovative product launches, partnerships, mergers, or acquisitions by leading companies in the Liquid Biopsy Market. The leading players have been analyzed by using research methodologies for getting insight views on global competition.

Contact Us:

UnivDatos

Contact Number - +1 978 733 0253

Email - contact@univdatos.com 

Website - www.univdatos.com

Linkedin- https://www.linkedin.com/company/univ-datos-market-insight/mycompany/